2-MeSADP

2-MeSADP (Serial dilutions) potently activates human SP174 (P2Y13) in HEK293-EBNA cells cotransfected with Gαq/i3, with an EC₅₀ of 19 nM, making it one of the most potent ligands tested for this receptor^[1].
2-MeSADP (Serial dilutions) potently activates mouse SP174 (P2Y13) in HEK293-EBNA cells cotransfected with Gαq/i3, with an EC₅₀ of 6.2 nM, showing higher potency at the murine receptor than the human ortholog^[1].
2-MeSADP (Serial dilutions; 10 min) potently inhibits forskolin-stimulated cAMP accumulation in HEK293-EBNA cells stably transfected with human SP174 (P2Y₁₃), with an EC₅₀ of 13 nM, confirming coupling of the receptor to Gαi signaling^[1].
2-MeS-ADP (Serial dilutions) potently activates human P2Y12 in HEK293-EBNA cells cotransfected with Gαq/i3, with an EC₅₀ of 5 nM, showing higher potency at P2Y12 than at the related SP174 (P2Y13) receptor^[1].
2-MeSADP (0.2 mg; 3 h) is partially susceptible to hydrolysis by alkaline phosphatase, with 87% degradation observed after a 3-hour incubation at 37 °C^[2].
2-MeSADP (40 mM; up to 24 h) exhibits moderate metabolic stability in human blood serum, with a half-life of 23.5 h at 37 °C^[2].
2-MeSADP (multiple concentrations) potently activates the turkey P2Y1 receptor expressed in human 1321N1 astrocytoma cells, inducing intracellular Ca ²⁺ mobilization with an EC₅₀ of 0.0025 μM^[2].
2-MeSADP (log M values of -7 to -5.5) induces aggregation and shape change in human platelets, and is 3-5 times more potent as an aggregating agent than ADP^[4].
2-MeSADP (log M values of -9 to -7; 2 min) potently inhibits PGE1-stimulated cyclic AMP accumulation in human platelets, with half-maximal inhibition at 6 nM in platelet-rich plasma and 2 nM in washed platelets, and is 150-200 times more potent than ADP for this effect^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.